Literature DB >> 26307391

HIF-2α regulates CDCP1 to promote PKCδ-mediated migration in hepatocellular carcinoma.

Manqing Cao1, Junrong Gao2, Hongyuan Zhou1, Jiafei Huang1, Abin You1, Zhigui Guo1, Feng Fang1, Wei Zhang1, Tianqiang Song3, Ti Zhang4.   

Abstract

Overexpression of CUB domain-containing protein 1 (CDCP1), a transmembrane glycoprotein and major substrate of Src family kinases (SFKs), always indicates unfavorable outcomes in various cancers. The characteristics of CDCP1 in hepatocellular carcinoma (HCC) have not been assessed. Most recently, CDCP1 was identified as a specific target gene of HIF-2α in clear cell renal carcinoma (CC-RCC). However, considering the role of HIF-2α in the progression of HCC is highly controversial, it is necessary to figure out whether HIF-2α and CDCP1 play a significant part in the metastasis of HCC. Our results showed that HIF-2α and CDCP1 were both induced by hypoxia, and the activation of CDCP1 was HIF-2α dependent. CDCP1 was governed by HIF-2α at mRNA and protein levels in HCC cell lines. Moreover, knocking down of HIF-2α not only inhibited cell invasion but also impaired the expression of Tyr(311) phosphorylation of protein kinase Cδ (PKCδ) which is a downstream factor of CDCP1 and has been reported to induce malignant migration in various tumors. Analysis of human HCC samples showed a negative correlation of CDCP1 expression with disease-free survival, and CDCP1 was an independent prognostic factors of disease-free survival. Taken together, these data demonstrated that HIF-2α could promote HCC cell migration by regulating CDCP1, and targeting HIF-2α-CDCP1-PKCδ pathway might be effective to inhibit HCC metastasis.

Entities:  

Keywords:  CDCP1; HIF-2α; Hepatocellular carcinoma; Metastasis; PKCδ

Mesh:

Substances:

Year:  2015        PMID: 26307391     DOI: 10.1007/s13277-015-3527-7

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  38 in total

1.  Establishment of cell clones with different metastatic potential from the metastatic hepatocellular carcinoma cell line MHCC97.

Authors:  Y Li; Z Y Tang; S L Ye; Y K Liu; J Chen; Q Xue; J Chen; D M Gao; W H Bao
Journal:  World J Gastroenterol       Date:  2001-10       Impact factor: 5.742

2.  HIFs enhance the migratory and neoplastic capacities of hepatocellular carcinoma cells by promoting EMT.

Authors:  Yang Liu; Yawei Liu; Xiaolu Yan; Yuan Xu; Fei Luo; Jing Ye; Han Yan; Xiaojun Yang; Xiaodan Huang; Jianping Zhang; Guozhong Ji
Journal:  Tumour Biol       Date:  2014-05-20

3.  Proteolysis-induced N-terminal ectodomain shedding of the integral membrane glycoprotein CUB domain-containing protein 1 (CDCP1) is accompanied by tyrosine phosphorylation of its C-terminal domain and recruitment of Src and PKCdelta.

Authors:  Yaowu He; Andreas Wortmann; Les J Burke; Janet C Reid; Mark N Adams; Ibtissam Abdul-Jabbar; James P Quigley; Richard Leduc; Daniel Kirchhofer; John D Hooper
Journal:  J Biol Chem       Date:  2010-06-15       Impact factor: 5.157

4.  Roles of hypoxia-inducible factor-1alpha (HIF-1alpha) versus HIF-2alpha in the survival of hepatocellular tumor spheroids.

Authors:  Heidi Menrad; Christian Werno; Tobias Schmid; Ekaterini Copanaki; Thomas Deller; Nathalie Dehne; Bernhard Brüne
Journal:  Hepatology       Date:  2010-06       Impact factor: 17.425

5.  Hypoxia-inducible factor-2 alpha (HIF-2 alpha) induces angiogenesis in breast carcinomas.

Authors:  Alexandra Giatromanolaki; Efthimios Sivridis; Aliki Fiska; Michael I Koukourakis
Journal:  Appl Immunohistochem Mol Morphol       Date:  2006-03

6.  Microarray-based identification of CUB-domain containing protein 1 as a potential prognostic marker in conventional renal cell carcinoma.

Authors:  Yasuo Awakura; Eijiro Nakamura; Takeshi Takahashi; Hirokazu Kotani; Yoshiki Mikami; Tadashi Kadowaki; Akira Myoumoto; Hideo Akiyama; Noriyuki Ito; Toshiyuki Kamoto; Toshiaki Manabe; Hitoshi Nobumasa; Gozoh Tsujimoto; Osamu Ogawa
Journal:  J Cancer Res Clin Oncol       Date:  2008-05-16       Impact factor: 4.553

7.  CUB domain-containing protein 1 is a novel regulator of anoikis resistance in lung adenocarcinoma.

Authors:  Takamasa Uekita; Lin Jia; Mako Narisawa-Saito; Jun Yokota; Tohru Kiyono; Ryuichi Sakai
Journal:  Mol Cell Biol       Date:  2007-09-04       Impact factor: 4.272

8.  Hypoxia-inducible factor-2alpha correlates to distant recurrence and poor outcome in invasive breast cancer.

Authors:  Karolina Helczynska; Anna-Maria Larsson; Linda Holmquist Mengelbier; Esther Bridges; Erik Fredlund; Signe Borgquist; Göran Landberg; Sven Påhlman; Karin Jirström
Journal:  Cancer Res       Date:  2008-11-15       Impact factor: 12.701

9.  Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer.

Authors:  Klarisa Rikova; Ailan Guo; Qingfu Zeng; Anthony Possemato; Jian Yu; Herbert Haack; Julie Nardone; Kimberly Lee; Cynthia Reeves; Yu Li; Yerong Hu; Zhiping Tan; Matthew Stokes; Laura Sullivan; Jeffrey Mitchell; Randy Wetzel; Joan Macneill; Jian Min Ren; Jin Yuan; Corey E Bakalarski; Judit Villen; Jon M Kornhauser; Bradley Smith; Daiqiang Li; Xinmin Zhou; Steven P Gygi; Ting-Lei Gu; Roberto D Polakiewicz; John Rush; Michael J Comb
Journal:  Cell       Date:  2007-12-14       Impact factor: 41.582

10.  Relation of hypoxia inducible factor 1 alpha and 2 alpha in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival.

Authors:  A Giatromanolaki; M I Koukourakis; E Sivridis; H Turley; K Talks; F Pezzella; K C Gatter; A L Harris
Journal:  Br J Cancer       Date:  2001-09-14       Impact factor: 7.640

View more
  12 in total

1.  FBXL14 abolishes breast cancer progression by targeting CDCP1 for proteasomal degradation.

Authors:  Yan-Hong Cui; Hyeonmi Kim; Minyoung Lee; Joo Mi Yi; Rae-Kwon Kim; Nizam Uddin; Ki-Chun Yoo; Jae Hyeok Kang; Mi-Young Choi; Hyuk-Jin Cha; Ok-Seon Kwon; In-Hwa Bae; Min-Jung Kim; Neha Kaushik; Su-Jae Lee
Journal:  Oncogene       Date:  2018-07-04       Impact factor: 9.867

2.  Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.

Authors:  Donglei Ji; Guanglei Shang; Enwei Wei; Yanjie Jia; Chunyu Wang; Qiang Zhang; Lei Zeng
Journal:  Oncogene       Date:  2022-05-05       Impact factor: 9.867

3.  miR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a.

Authors:  Man-Qing Cao; A-Bin You; Xiao-Dong Zhu; Wei Zhang; Yuan-Yuan Zhang; Shi-Zhe Zhang; Ke-Wei Zhang; Hao Cai; Wen-Kai Shi; Xiao-Long Li; Kang-Shuai Li; Dong-Mei Gao; De-Ning Ma; Bo-Gen Ye; Cheng-Hao Wang; Cheng-Dong Qin; Hui-Chuan Sun; Ti Zhang; Zhao-You Tang
Journal:  J Hematol Oncol       Date:  2018-01-24       Impact factor: 17.388

4.  Decreased expression of acetyl-CoA synthase 2 promotes metastasis and predicts poor prognosis in hepatocellular carcinoma.

Authors:  Lin Sun; Yinlong Kong; Manqing Cao; Hongyuan Zhou; Huikai Li; Yunlong Cui; Feng Fang; Wei Zhang; Jiafeng Li; Xiaolin Zhu; Qiang Li; Tianqiang Song; Ti Zhang
Journal:  Cancer Sci       Date:  2017-05-20       Impact factor: 6.716

5.  The PDGFRβ/ERK1/2 pathway regulates CDCP1 expression in triple-negative breast cancer.

Authors:  Luca Forte; Federica Turdo; Cristina Ghirelli; Piera Aiello; Patrizia Casalini; Marilena Valeria Iorio; Elvira D'Ippolito; Patrizia Gasparini; Roberto Agresti; Beatrice Belmonte; Gabriella Sozzi; Lucia Sfondrini; Elda Tagliabue; Manuela Campiglio; Francesca Bianchi
Journal:  BMC Cancer       Date:  2018-05-23       Impact factor: 4.430

6.  Cell-Surface Protein Profiling Identifies Distinctive Markers of Progenitor Cells in Human Skeletal Muscle.

Authors:  Akiyoshi Uezumi; Masashi Nakatani; Madoka Ikemoto-Uezumi; Naoki Yamamoto; Mitsuhiro Morita; Asami Yamaguchi; Harumoto Yamada; Takehiro Kasai; Satoru Masuda; Asako Narita; Yuko Miyagoe-Suzuki; Shin'ichi Takeda; So-Ichiro Fukada; Ichizo Nishino; Kunihiro Tsuchida
Journal:  Stem Cell Reports       Date:  2016-08-09       Impact factor: 7.765

7.  CUB domain-containing protein 1 and the epidermal growth factor receptor cooperate to induce cell detachment.

Authors:  Mary E Law; Renan B Ferreira; Bradley J Davis; Paul J Higgins; Jae-Sung Kim; Ronald K Castellano; Sixue Chen; Hendrik Luesch; Brian K Law
Journal:  Breast Cancer Res       Date:  2016-08-05       Impact factor: 6.466

8.  New crossroads for potential therapeutic intervention in cancer - intersections between CDCP1, EGFR family members and downstream signaling pathways.

Authors:  Yaowu He; Brittney S Harrington; John D Hooper
Journal:  Oncoscience       Date:  2016-01-29

9.  OSU-2S/Sorafenib Synergistic Antitumor Combination against Hepatocellular Carcinoma: The Role of PKCδ/p53.

Authors:  Hany A Omar; Mai F Tolba; Jui-Hsiang Hung; Taleb H Al-Tel
Journal:  Front Pharmacol       Date:  2016-11-30       Impact factor: 5.810

10.  CDCP1 is a novel marker of the most aggressive human triple-negative breast cancers.

Authors:  Federica Turdo; Francesca Bianchi; Patrizia Gasparini; Marco Sandri; Marianna Sasso; Loris De Cecco; Luca Forte; Patrizia Casalini; Piera Aiello; Lucia Sfondrini; Roberto Agresti; Maria Luisa Carcangiu; Ilaria Plantamura; Gabriella Sozzi; Elda Tagliabue; Manuela Campiglio
Journal:  Oncotarget       Date:  2016-10-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.